64B13-18.002. Formulary of Topical Ocular Pharmaceutical Agents  


Effective on Friday, March 13, 2020
  • 1The formulary of topical ocular pharmaceutical agents consists of pharmaceutical agents that are appropriate to treat or diagnose ocular disease and disorders and which a certified optometrist is qualified to administer and prescribe in the practice of optometry pursuant to Section 42463.0055(2)(a), F.S. 44The topical ocular pharmaceutical agents in the formulary include the following legend drugs alone or in combination in concentrations up to those specified, or any lesser concentration:

    71(1) CYCLOPLEGIC AND MYDRIATICS

    75(a) Atropine sulfate – 1.0% (solution and ointment);

    83(b) Phenylepherine HCl – 2.5%;

    88(c) Cyclopentolate HCl – 0.5%, 1.0%;

    94(d) Scopolamine HBr – 0.25%;

    99(e) Homatropine HBr – 2.0%, 5.0%;

    105(f) Tropicamide – 0.5%, 1.0%; and,

    111(g) Hydroxyamphetamine HBr – 1.0% plus tropicamide – 0.25%.

    120(2) LOCAL ANESTHETICS

    123(a) Tetracaine – 0.5%;

    127(b) Proparacaine HCl – 0.5%; and,

    133(c) Benoxinate HCl – 0.4% (in combination with fluorescein).

    142(3) DIAGNOSTIC PRODUCTS

    145Fluorescein paper strips – 1 mg, 9 mg per strip.

    155(4) ANTIBACTERIAL

    157(a) Erythromycin – 0.5%;

    161(b) Bacitracin – 400 units/g, 500 units/g (ointment alone and in combination);

    173(c) Polymyxin – 10,000 units/g (only in combination);

    182(d) Neomycin – 1.75 mg/g, 1.75 mg/ml, 3.50 mg/g (only in combination);

    194(e) Gentamicin – 0.3% (solution and ointment);

    201(f) Tobramycin – 0.3% (solution and ointment in combination);

    210(g) Gramicidin – 0.025 mg/ml (only in combination);

    218(h) Ciprofloxacin HCl – 0.3% (solution and ointment);

    226(i) Trimethoprim – 1.0 mg/ml (only in combination);

    234(j) Ofloxaxin – 0.3%;

    238(k) Levofloxacin – 1.5%;

    242(l) Gatifloxacin – 0.5%;

    246(m) Moxifloxacin – 0.5%;

    250(n) Sodium sulfacetamide – 10.0% (alone and in combination);

    259(o) Azithromycin – 1%; and,

    264(p) Besifloxacin Ophthalmic Suspension – 0.6%.

    270(5) NON-STEROIDAL AND STEROIDAL ANTI-INFLAMMATORY AGENTS

    276(a) Medrysone – 1.0%;

    280(b) Prednisolone acetate – 0.12%, 0.125%, 0.2%, 0.5%, 0.6%, 1.0% (alone and in combination);

    294(c) Prednisolone sodium phosphate – 0.125%, 0.25%, 1.0% (alone and in combination);

    306(d) Flurometholone – 0.1%, 0.25% (suspension and ointment, alone and in combination);

    318(e) Dexamethasone – 0.1%, 1.0% (alone and in combination), 0.4 mg ophthalmic insert;

    331(f) Fluorometholone acetate – 0.1%;

    336(g) Rimexolone – 1.0%;

    340(h) Loteprednol etabonate – 0.2%, 0.5% (alone and in combination);

    350(i) Diclofenac sodium – 0.1%;

    355(j) Ketorolac tromethamine – 0.5%;

    360(k) Hydrocortisone – 1.0% (only in combination);

    367(l) Bromfenac – .09%;

    371(m) Nepafenac – 0.1%; and,

    376(n) Difluprednate ophthalmic emulsion – .05%

    382(o) Loteprednol etabonate ophthalmic suspension – 1%.

    389(6) ANTIHISTAMINES, MAST CELL STABILIZERS AND ANTI-ALLERGY AGENTS

    397(a) Cromolyn sodium – 4.0%;

    402(b) Lodoxamide tromethamine – 0.1%;

    407(c) Olopatadine HCl – 0.7%;

    412(d) Nedocromil sodium – 2.0%;

    417(e) Azelastine HCl – 0.05%:

    422(f) Pemirolast potassium – 0.1%;

    427(g) Epinastine HCl – 0.05%;

    432(h) Bepotastine besilate – 1.5%; and,

    438(i) Alcaftadine – .25%.

    442(7) ANTIVIRAL AGENTS

    445(a) Trifluridine – 1.0%;

    449(b) Ganciclovir – 0.15%; and,

    454(c) Povidone-iodine ophthalmic solution 5%.

    459(8) ANTI-GLAUCOMA AGENTS

    462(a) Beta Blockers.

    4651. Betaxolol HCl – 0.25%, 0.5%;

    4712. Levobunolol HCl – 0.25%, 0.5%;

    4773. Metipranolol HCl – 0.3%;

    4824. Timolol maleate or hemihydrate – 0.25%, 0.5% (solution and gel, alone and in combination); and,

    4985. Carteolol HCl – 1.0%.

    503(b) Miotics, Direct-acting

    5061. Carbachol – 0.75%, 1.5%, 3.0%;

    5122. Pilocarpine HCl – 0.5%, 1.0%, 2.0%, 4.0%; and,

    5213. Pilocarpine gel – 4.0%.

    526(c) Prostaglandins

    5281. Latanoprost – 0.005%;

    5322. Bimatoprost – 0.03%;

    5363. Travoprost – 0.004%;

    5404. Tafluprost – 0.0015%;

    5445. Unoprostone Isoprophyl – 0.15%; and,

    5506. Latanoprostene Bunod Ophthalmic Solution – 0.024%.

    557(d) Alpha5592 560Adrenergic Agonist

    5621. Brimonidine tartrate – 0.15%, 0.2%; and,

    5692. Apraclonidine HCl – 0.5%.

    574(e) Carbonic Anhydrase Inhibitors (CAI’s)

    5791. Brinzolamide – 1.0%; and,

    5842. Dorzolamide HCl – 2.0% (alone and in combination).

    593(f) Rho Kinase Inhibitor – Netarsudil – 0.02%;

    601(9) MISCELLANEOUS

    603(a) Hydroxypropyl cellulose ophthalmic Insert;

    608(b) Dapiprazole – 0.5%;

    612(c) Cyclosporine emulsion or solution – 0.1%;

    619(d) Polyvinyl pyrrolidone – drops 2.0%;

    625(e) Bimatoprost – .03%;

    629(f) Natamycin Ophthalmic Suspension 5%;

    634(g) Lifitegrast ophthalmic solution 5%; and,

    640(h) Cyclosporine 0.09% Ophthalmic Solution.

    645Rulemaking Authority 647463.005, 648463.0055(2)(a) FS. 650Law Implemented 652463.0055 FS. 654History–New 3-30-87, Amended 4-5-88, 5-7-90, Formerly 21-18.002, Amended 5-10-92, 1-29-93, Formerly 21Q-18.002, Amended 8-31-93, 7-30-94, Formerly 61F8-18.002, Amended 2-11-96, 4-21-96, 1-12-97, 6-8-97, Formerly 59V-18.002, Amended 6-15-00, 6-7-05, 6-10-06, 6-26-08, 10-16-08, 3-23-09, 6-28-09, 10-18-09, 4-21-10, 12-26-10, 7-21-11, 11-11-12, 11-29-13, 12-9-13, 4-10-14, 8-14-15, 1-20-17, 8-31-18, 1-25-19, 8-5-19, 3-13-20.

     

Historical Versions(18)

Select effective date to view different version.

Related Statutes: